Perceptions of Leadership in Quality Culture for Infection Prevention Among Intensive Care Nurses and Unit-Based Assessment of Antimicrobial Resistance Indicators in Intensive Care Units
This study aims to examine intensive care nurses' perceptions of leadership in quality culture for infection prevention and to investigate antimicrobial resistance indicators at the intensive care unit level. Healthcare-associated infections (HAIs) remain a major global patient safety problem and are associated with prolonged hospital stays, increased healthcare costs, and higher mortality. The increasing prevalence of antimicrobial resistance (AMR) further complicates infection prevention and patient care.
Intensive care units are particularly vulnerable to healthcare-associated infections and antimicrobial resistance because of the high frequency of invasive procedures, the vulnerability of critically ill patients, and the extensive use of broad-spectrum antibiotics. Nurses play a central role in infection prevention and antimicrobial stewardship because they are continuously involved in patient care. However, previous studies have reported a gap between nurses' knowledge of infection prevention and adherence to recommended practices in clinical settings. Organizational culture and leadership may contribute to this gap.
Most previous studies have focused on healthcare professionals' self-reported perceptions of infection prevention. However, limited evidence is available regarding the relationship between nurses' perceptions of leadership and quality culture and objective antimicrobial resistance indicators at the intensive care unit level. Therefore, this study will assess nurses' perceptions using the Leadership in Quality Culture for Infection Prevention (LCQ-IP) instrument and examine their relationship with retrospective microbiological data from the participating intensive care units, including antimicrobial resistance rates and resistance profiles. The findings may provide evidence on the role of organizational leadership and quality culture in infection prevention and antimicrobial resistance management in intensive care settings.
Studieoversikt
Status
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Yeliz Alakan, PhD lecturer
- Telefonnummer: 90 505 850 0222
- E-post: yelizsapulu@uludag.edu.tr
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Nurses who have been actively working in an intensive care unit for at least 1 year.
- Nurses who voluntarily agree to participate in the study.
Exclusion Criteria:
- Student nurses or nursing interns.
- Nurses working temporarily or on a rotational basis in the intensive care unit.
- Nurses who have been actively working in an intensive care unit for at least 1 year.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Bursa
Intensive Care Nurses and Intensive Care Units in Bursa
|
|
Iğdır
Intensive Care Nurses and Intensive Care Units in Iğdır
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Leadership in Quality Culture for Infection Prevention (LCQ-IP) score among intensive care nurses
Tidsramme: Baseline
|
Leadership for a culture of quality in infection prevention will be assessed using the Turkish version of the Leading a Culture of Quality for Infection Prevention Scale.
The scale consists of 16 items rated on a 5-point Likert scale.
Total scores range from 16 to 80, with higher scores indicating a more positive perception of leadership for a culture of quality in infection prevention.
|
Baseline
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Antimicrobial Susceptibility Profiles of Bacterial Isolates from Intensive Care Units
Tidsramme: The 1-year period preceding study enrollment
|
The 1-year period preceding study enrollment
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- Quality Culture (LCQ-IP)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .